At the Global Bio-India 2023 summit, Japan-headquartered pharmaceutical company Takeda signed a three-year Memorandum of Understanding with India’s Biotechnology Industry Research Assistance Council (BIRAC), a state-owned entity.
Under the agreement, Takeda will provide advisory and mentoring support to Indian innovators and entrepreneurs to help them develop new healthcare solutions from idea conception to market launch.
The collaboration aligns with BIRAC’s vision to stimulate, foster and enhance the strategic research and innovation capabilities of the Indian biotech industry for creation of affordable products addressing the needs of society.
Serina Fischer, Takeda’s General Manager in India, said that the company’s vision matches the Indian government’s goal for locally-developed solutions to global health challenges. Fischer noted that the partnership serves as a model for how public and private entities can collaborate to drive major, lasting healthcare advances.
Ruchi Sogarwal, Head of Takeda India’s Corporate Affairs, added “Collaborations between the government, academia and industry contribute immensely to accelerating innovation and building disruptive healthcare technology solutions for addressing unmet patient needs. Our partnership with BIRAC will allow us to foster innovations, nurture capabilities and enhance global competitiveness translating bioscience into bioeconomy.”
Last updated: December 26th, 2025
